



औषध विभाग
Department of
Pharmaceuticals



INTERNATIONAL CONFERENCE ON PHARMA AND MEDICAL DEVICE SECTOR

9TH



March 2025 | New Delhi

PROPOSED COMPONENTS

Thematic conference sessions on Pharma and Medical Devices Sector

CEO Roundtable

Chaired by Shri J. P. Nadda, Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers

Proposed Workshops - Pharmacovigilance, Jan Aushadhi Initiative

Regulators Meet

Industry interaction with Central & State Drug Regulators


Industry-Academia Collaboration

Leveraging Expertise from **NIPERs** and Other Academic Institutes

Global Partnership Enhancing India Pharmaceutical Industry

Start-Up Pitching Session

States Investment Session



ABOUT

INDIA PHARMA & INDIA MEDICAL DEVICE 2025

The Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, along with the Federation of Indian Chambers of Commerce & Industry (FICCI) has been actively working towards growth of Pharma & Medical Device sector. Since the objective has always been to encourage and bring forward best technology solutions and manufacturing, therefore, Department of Pharmaceuticals announced India Pharma & India Medical Device series of events which is an annual activity. The 9th edition of International Conference on Pharmaceutical & Medical Device sector i.e **INDIA PHARMA 2025** & **INDIA MEDICAL DEVICES 2025** is scheduled in March, 2025.

The objective of India Pharma & India Medical Device 2025 is to:

- Endeavor to address industry issues and to create a platform to recommend solutions
- Facilitate sharing of knowledge and best practices
- Promote India as a Manufacturing hub in the Pharmaceutical and Medical Devices Sector
- Establish India as a premier global healthcare destination and attract investments
- Provide a platform to network and collaborate
- Identify new priority areas and deliberate upon them



PHARMA SECTOR OVERVIEW

The Indian Pharmaceutical industry, often referred to as the "Pharmacy of the World", contributes immensely to global public health and promoting universal healthcare access. India is 3rd largest global player in Drugs and pharmaceuticals by volume estimated at a size of \$ 50 billion in 2022-23, and exports account for 50% of this no. It is anticipated to reach a size of more than double to USD 130 bn by 2030. India's pharmaceutical exports reached USD 27.85 billion in FY24, growing 9.66%. Pharmaceuticals account for 9.67% of India's merchandise exports; drug formulations and biologicals are the second-largest export. 10 of the top 25 global generic drug companies are from India.

Market size of India pharmaceuticals industry is expected to reach US\$ 65 billion by 2024, and ~US\$ 130 billion by 2030. Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics.

Indian pharmaceutical industry plays significant role globally, supplying affordable and low-cost generic drugs to millions of people across the globe. The



sector offers lower cost without compromising on quality as is reflected by the fact India has the highest number of United States Food and Drug Administration (USFDA) approved pharmaceutical plants outside the US and also a significant number of World Health Organization (WHO) Good Manufacturing Practices (GMP)- compliant plants as well as plants approved by regulatory authority of other countries. India accounts for 60 percent of global vaccine production, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine. There are 500 API manufacturers contributing about 8% in the global API Industry. India is the largest supplier of generic medicines and manufactures about 60,000 different generic brands across 60 therapeutic categories and accounts for 20% of the global supply of generics. Because of the low price and high quality, Indian medicines are preferred worldwide, making it “Pharmacy of the World”.

India's pharmaceutical sector forms a major component of the country's foreign trade and has been consistently making trade surplus. The Government has put in place an investor-friendly Foreign Direct Investment (FDI) policy to promote investment in the Sector. In pharmaceuticals, up to 100% FDI in greenfield projects and up to 74% FDI in brownfield projects is allowed under the automatic route. The booming pharmaceutical industry of India is largely driven by cost-effective innovation when it comes to mass production of life saving drugs that are used by countries globally. During the Covid-19 pandemic, India was at the forefront of delivering essential drugs and vaccines to several nations. India's 500 API manufacturers contribute 8% to the global API industry. With the immense potential for growth, pharmaceuticals sector is set to attain new heights in a post-pandemic world and elevate its position on the value chain by delivering affordable and quality- assured medicines and addressing the unmet needs of patients across the globe.



MEDICAL DEVICE SECTOR OVERVIEW

The Indian Government has prioritized the medical devices sector as part of its flagship 'Make in India' initiative, aimed at bolstering the manufacturing ecosystem. Currently valued at approximately \$15.35 billion in 2023, the Indian medical devices market is projected to reach \$20.51 billion by 2029, growing at a CAGR of 5.35%. Over the past three years, the sector has experienced a remarkable CAGR of 15%.

India is the fourth largest medical devices market in Asia, following Japan, China, and South Korea, and ranks among the top 20 globally, holding about 1.65% of the worldwide market share. In the fiscal year 2022-23, India exported medical consumables and disposables worth \$1.6 billion, surpassing imports of around \$1.1 billion, marking a 16% increase in exports and a 33% decrease in imports. However, between November 2022 and October 2023, imports surged by 21%, amounting to ₹61,262.84 crore (approximately \$7.23 billion). The medical devices sector in India is divided into the following segments: These segments highlight the diverse nature of the medical devices industry, each playing a crucial role in healthcare delivery and improving patient outcomes.

Consumables & Disposables: Items that are used once or a limited number of times, such as needles, syringes, surgical gloves, catheters, and bandages.

Diagnostic Imaging: Equipment used for imaging and diagnostics, including MRI machines, CT scanners, ultrasound devices, X-ray machines, and fluoroscopy systems.

Therapeutic Devices: Devices designed for treatment, such as infusion pumps, dialysis machines, and respiratory devices like nebulizers

and ventilators.

Dental Products: Products used in dental care, including crowns, bridges, dentures, braces, and diagnostic tools like dental X-ray equipment.

Orthopaedics & Prosthetics: Devices that support or replace damaged or missing body parts, such as knee implants, hip replacements, and artificial limbs.

Patient Monitoring Devices: Equipment used to monitor patients' vital signs, including ECG monitors, blood pressure monitors, pulse oximeters, and glucose monitors.

Surgical Instruments: Tools used in surgical procedures, such as scalpels, forceps, clamps, and suturing devices.

In vitro Diagnostic Devices: Tests and devices used to diagnose diseases or conditions by examining samples from the body, such as blood test kits, reagents, and analyzers.

Wearable Devices: Technology that can be worn on the body to monitor health metrics, such as fitness trackers, smartwatches, and wearable ECG monitors.

Rehabilitation Devices: Equipment that aids in recovery and rehabilitation, such as physiotherapy devices, mobility aids (wheelchairs, crutches), and orthotic devices.

Implantable Devices: Devices that are surgically implanted in the body, including pacemakers, stents, and cochlear implants.

Hospital Equipment: Equipment used in healthcare facilities for patient care, such as hospital beds, surgical tables, and medical gas delivery systems.

With approximately 750-800 domestic manufacturers representing 65% of the market, India boasts a diverse medical device startup ecosystem with over 250 organizations focused on innovative solutions to significant health challenges.

To enhance manufacturing capabilities and strengthen India's position in the global medical devices market, as well as to promote innovation and growth within the sector, the Government of India has launched several initiatives:

- **Medical Device Clusters and Parks:** Establishing dedicated clusters across states like Himachal Pradesh, Tamil Nadu, Madhya Pradesh, and Uttar Pradesh to support domestic manufacturing with standardized testing and infrastructure.
- **National Medical Policy:** In November 2023, six strategies were developed as part of this policy, accompanied by a comprehensive action plan for implementation.
- **100% Foreign Direct Investment (FDI):** The sector permits 100% FDI, especially in equipment, instruments, consumables, and implants.
- **Production-Linked Incentive (PLI) Scheme:** This scheme incentivizes domestic manufacturing in the medical devices sector by providing financial support based on production levels. It aims to boost manufacturing capabilities and attract investments.
- **National Health Mission (NHM):** While primarily focused on health service delivery, NHM also supports the procurement and supply of medical devices and equipment for healthcare facilities, enhancing the overall healthcare infrastructure.
- **Export Promotion Council:** Established in May

2023 under the Department of Pharmaceuticals in Noida, this council aims to facilitate exports in the sector.

- **Scheme for Strengthening the Medical Device Industry:** Department of Pharmaceuticals recently launched this scheme with a total outlay of 500 crores to strengthen the Medical Devices Industry. This comprehensive scheme targets critical areas of the medical device industry covering manufacturing of key components and accessories, skill development, support for clinical studies, development of common infrastructure and industry promotion. This scheme is poised to be a game-changer, benefiting the industry while making a significant stride toward India's self-reliance.

The medical devices sector in India is on the brink of significant transformation, fueled by government initiatives and a growing ecosystem of domestic manufacturers and innovators. With the backing of the 'Make in India' initiative and various supportive schemes the industry is poised for robust growth. As the market expands, driven by increasing healthcare demands and advancements in technology, India has the potential to emerge as a global hub for medical devices.

By fostering collaboration among stakeholders, encouraging innovation, and enhancing manufacturing capabilities, the country can not only meet its domestic healthcare needs but also strengthen its position in the global market. The Meditech Expo 2025 and India Medical Devices Conference 2025 serves as a vital platform for dialogue, knowledge sharing, and partnership, paving the way for a healthier future. Together, we can drive innovation, support industry growth, and improve healthcare outcomes for all.

PROPOSED CONFERENCE PROGRAM

DAY 1

10:00 - 11:00	Inaugural Ceremony - India Pharma and India Medical Devices Annual Conference (Launch of Knowledge Report)	
11:00 - 11:15	Tea Break	
11:15 - 13:30	INDIA PHARMA CEO Roundtable with Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Gol (By Invitation Only)	IP Workshop 01: Jan Aushadhi Initiative
13:30 - 14:30	Lunch break	
14:30 - 15:30	India Medical Devices CEO Roundtable with Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Gol (By Invitation Only)	IP Workshop 02: In association with IPC onarmacovigilance
15:30 - 15:45	Tea Break	
15:45 - 16:45	Regulators Meet: Industry interaction with Central & State Drug Regulators	
16:45 - 17:15	Tea Break	
17:15 - 18:30	States Investment Session	
19:30 Onwards	Dinner hosted by Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Gol (By Invitation Only)	

DAY 2

10:00 - 11:30	IP 01: India as a Vaccine Manufacturing Destination & Biosimilars: Driving Innovation, Affordability, and Global Competitiveness in Healthcare	
11:30 - 11:45	Tea Break	
11:45 - 13:00	IP 02: Pharma Moonshots: Pioneering Innovation and Transformative R&D for the Future	Start-up Pitching Session
13:00 - 14:00	Lunch Break	
14:00 - 15:30	IP 03: Contract Research and Manufacturing: Catalyzing Growth for India Pharma's Global Reach	Global Partnership Enhancing India Pharmaceuticals industry
15:30 - 15:45	Tea Break	
16:00 - 17:30	Valedictory Session	

DAY 1

Time	Sessions
10:00 - 11:00	Inaugural Session: 9th Edition of India Pharma and India Medical Device Annual Conference
11:00 - 11:15	Tea Break
11:15 - 13:30	INDIA PHARMA CEO Roundtable with Hon'ble Minister for Chemicals & Fertilizers, Dept of Pharmaceuticals with Government of India (By Invitation Only)
11:15 - 13:30	<p>IP Workshop 01: Jan Aushadhi Initiative</p> <p>Workshop Brief Details and Objectives: -</p> <p>The Jan Aushadhi initiative is a transformative effort to provide affordable generic medicines, significantly reducing healthcare costs for consumers. With over 10,000 Jan Aushadhi Kendras across India, offering more than 800 medicines and 154 surgical items at prices at least 50% cheaper, the program has led to an estimated annual savings of ₹ 10,000 crore for consumers. By setting maximum retail prices, ensuring high-quality standards, and eliminating intermediaries in procurement and distribution, the initiative enhances accessibility and trust. Additional incentives, financial support for manufacturers, and public awareness campaigns further bolster the impact of this program, empowering both consumers and healthcare providers.</p> <p>Expected Outcome</p> <p>Participants will gain a comprehensive understanding of the Jan Aushadhi initiative's impact on reducing healthcare costs and improving access to affordable medicines, and will identify actionable strategies to further enhance outreach, efficiency, and public awareness.</p>
13:30 - 14:30	Lunch Break
14:30-15:30	India Medical Devices CEO Roundtable with Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Government of India (By Invitation Only)
Parallel	<p>IP Workshop 02: Workshop in association with IPC on Pharmacovigilance</p> <p>Workshop Brief Details and Objectives: -</p> <p>Workshop on Pharmacovigilance: Ensuring Drug Safety</p> <p>This workshop will focus on the critical role of pharmacovigilance in monitoring and improving drug safety. The workshop on pharmacovigilance will offer a comprehensive exploration of key topics essential for ensuring drug safety and patient well-being. These will include the importance of pharmacovigilance in safeguarding patient safety, best practices for adverse drug reaction (ADR) reporting systems, and adherence to regulatory compliance and global safety standards. Participants will also engage with case studies showcasing effective pharmacovigilance implementation in real-world settings. Designed for healthcare professionals, researchers, and regulatory authorities, the workshop aims to enhance expertise in drug safety monitoring, foster collaboration across stakeholders, and promote a culture of patient-centred care.</p>

	<p>Expected Outcome</p> <p>Participants will develop a deeper understanding of pharmacovigilance principles, ADR reporting systems, and regulatory compliance, enabling them to implement effective drug safety practices and contribute to a patient-centric approach in healthcare delivery.</p>
15:30 - 15:45	Tea Break
15:45 - 16:45	<p>Regulators Meet: Industry interaction with Central & State Drug Regulators</p> <p>This interaction will facilitate a constructive dialogue on enhancing the regulatory framework for the pharmaceuticals and medical devices sectors in our country. It will focus on identifying and adopting effective regulatory practices to foster mutual alignment, enabling the establishment of collaborative channels for superior trade, regulation, and manufacturing environments. The interaction between industry representatives and regulators will centre on proactive discussions to address industry concerns, strengthen synergies, and ensure optimal compliance while encouraging the development of safe and effective drugs and products. This regulators meet will entail Critical challenges in the Pharma sector hindering growth., strategies to address regulatory barriers affecting import/export activities, establishing mechanisms for extended dialogue between regulators to enhance knowledge sharing and skill development, opportunities and obstacles in achieving regulatory harmonization and potential role of state drug regulators in driving sectoral growth.</p> <p>Expected Outcome: The session will feature a question-and-answer format, allowing industry representatives to seek clarifications and raise specific concerns directly with regulators. It provides a platform for open dialogue, enabling stakeholders to voice their issues and contribute to shaping effective regulatory frameworks. This interaction fosters mutual understanding, promotes compliance, and drives continuous improvement in the pharmaceutical sector.</p>
16:45 - 17:15	Tea Break
17:15 - 18:30	<p>States Investment Session</p> <p>Session Brief:</p> <p>India's \$50 billion pharmaceutical industry, projected to expand to \$450 billion by 2047, is a global leader and a top destination for investors. Renowned as the "pharmacy of the world," India supplies medicines to over 200 countries. This session will delve into the diverse investment opportunities in the pharma sector. Facilitate strategic dialogue between industry and state governments to identify investment opportunities, improve supply chain integration through manufacturing and innovation in the sector, promote the benefits and opportunities in Bulk Drug Parks, establish an affordable and accessible pharma ecosystem in India to collectively improve public health outcomes, and extend opportunities for knowledge sharing between the government and industry to enhance the scope of the industry. The session will briefly have objective to highlight pharma manufacturing opportunities across Indian states, promotion of Bulk Drug Parks, showcase of state-specific investment opportunities and incentives for pharmaceutical companies, Strengthen collaborations between state governments and the pharmaceutical industry to enhance linkages.</p> <p>Expected Outcome: To showcase investment opportunities and development prospects across Indian states in the pharmaceutical sector, encompassing generics, APIs, biosimilars, CRAMS, and digital health. It will explore government initiatives such as PLI schemes and regulatory reforms designed to attract investments and accelerate industry growth. Additionally, the session will foster strategic partnerships and collaborations among investors, industry leaders, and government stakeholders to drive innovation and development in the sector.</p>
19:30 Onwards	Dinner hosted by Minister

Day 2

IP 01: India as a Vaccine Manufacturing Destination & Biosimilars: Driving Innovation, Affordability, and Global Competitiveness in Healthcare

Session Brief:

India has positioned itself as a global powerhouse in vaccine manufacturing, producing 60% of the world's vaccines and supplying to over 150 countries. The country's vaccine market is expected to reach \$2.4 billion in 2025, growing at a CAGR of 18%. India's vaccine production landscape, comprising more than 30 major manufacturers, has proven its capability to innovate and mass-produce cost-effective, high-quality vaccines. This was successfully demonstrated during the COVID-19 pandemic with India supplying vaccines to 1.4 billion people in India and 242 million to 101 other countries. This session will explore India's strengths in vaccine manufacturing, including its robust infrastructure, skilled workforce, and cost-effective production. Biosimilars are transforming healthcare by driving innovation, enhancing affordability, and boosting global competitiveness. These biologic products offer cost-effective alternatives to expensive reference biologics, improving patient access to critical therapies for chronic and life-threatening diseases. By fostering innovation in manufacturing processes and regulatory frameworks, biosimilars are not only reducing healthcare costs but also positioning India as a global leader in biopharmaceutical production.

Expected Outcomes: This session aims to explore how collaboration and strategic dialogue can tackle industry challenges, leverage opportunities, and adapt to emerging trends. Key areas of focus include effective vaccine deployment, disease prevention, and critical policy measures. The discussion seeks to improve patient access to healthcare, drive economic growth, and strengthen India's global competitiveness while enhancing the ease of doing business. The session will further explore strategies to scale biosimilar adoption, promote investments, and enhance collaboration between industry and government to unlock their full potential in delivering equitable healthcare solutions worldwide.

10:00 - 11:30

11:30 - 11:45

Tea Break

IP 02: Pharma Moonshots: Pioneering Innovation and Transformative R&D for the Future

Session Brief:

In an era defined by rapid technological advancements and evolving healthcare demands, the Indian pharmaceutical industry has a pivotal role in shaping the future of global healthcare. As the largest producer of generic medicines, India has significantly contributed to affordable healthcare worldwide. However, maintaining this leadership requires a paradigm shift towards innovation-driven research and transformative R&D. This session will delve into the critical need for India to foster cutting-edge pharmaceutical innovation, focusing on breakthrough therapies, advanced manufacturing, and novel drug development. It will explore actionable strategies to strengthen the industry's global competitiveness, address pressing healthcare challenges such as accessibility and affordability, and align with sustainable growth goals.

Expected Outcome: This session will explore the global healthcare landscape, focusing on innovations in biopharmaceuticals, biosimilars, digital health, nanotechnology, and personalized medicine. It will highlight strategies to accelerate growth through policy support and incentives, positioning India as a leader in both generics and cutting-edge pharmaceutical advancements.

11:45 - 13:00

Parallel	<p>Start-up Pitching Session</p> <p>Session Brief:</p> <p>The Biotech & Pharma Startup Pitch Session is a vibrant platform designed to spotlight groundbreaking biotech and pharmaceutical startups while fostering collaborations, securing funding, and advancing national health priorities. This event brings together a diverse audience, including startups, pharma giants, venture capitalists, government officials, and healthcare professionals, to drive innovation in areas such as drug development, digital health, personalized medicine, and affordable healthcare. By showcasing transformative ideas, facilitating partnerships, and aligning with regulatory and access challenges, the session aims to catalyze impactful solutions that address critical healthcare needs, offering unparalleled opportunities for innovators, investors, and stakeholders to collaborate on shaping the future of health.</p> <p>Expected Outcome:</p> <p>Interactive sessions with investors and mentors will provide selected startups with valuable networking opportunities, enabling them to connect with potential investors, strategic partners, and industry experts to accelerate their growth and success.</p>
13:00 - 14:00	<p>Lunch Break</p>
14:00 - 15:30	<p>IP 03: Contract Research and Manufacturing: Catalyzing Growth for India Pharma's Global Reach</p> <p>Brief session flow:</p> <p>This session highlights the critical role of contract research and manufacturing services (CRAMS) in expanding the global footprint of the Indian pharmaceutical industry. It will delve into strategies to enhance CRAMS capabilities, foster innovation, and build robust international partnerships. Key discussions will focus on leveraging India's expertise in drug development and manufacturing, scaling operations to meet global quality standards, overcoming supply chain challenges, and unlocking collaboration opportunities with global pharma players. Participants will gain valuable insights into industry trends, market demands, and success stories, reinforcing India's position as a trusted partner in the global healthcare ecosystem and driving sustained growth in international markets.</p> <p>Expected outcomes: This session will provide insights into scaling CRAMS operations to meet global standards, fostering innovation, and building international partnerships. The session will equip stakeholders to address supply chain challenges, leverage India's expertise, and seize collaboration opportunities with global pharma players. These outcomes aim to position India as a leading partner in the global healthcare ecosystem, driving sustained growth and market expansion.</p>
Parallel	<p>Global Partnership Enhancing India Pharmaceuticals industry</p> <p>Session Brief:</p> <p>Globalization has enabled numerous Indian pharmaceutical companies to extend their operations internationally. Shifts in regulatory, patent, and market trends are creating significant opportunities for generic drugs, positioning Indian pharma companies to capitalize on these prospects in the global marketplace. However, many Indian pharmaceutical companies face substantial challenges in global markets. The session will help to deliberate on key aspects to boost Global Partnerships Enhancing India's Pharmaceuticals Sector. These include the identification of Global Best Practices, Market Diversification, Technology Transfer and R&D Collaborations process bottlenecks that impede investments for pharma industry. A related point of focus will be the Improved Compliance, Global Regulatory Overview: Presentations by International Regulators on their regulatory frameworks, latest updates and areas of focus sharing within the Pharma sector, where various stakeholders collaborate to optimize resources and capabilities. Taking a broader perspective, the global dimension of pharma sector will be considered, examining global mechanisms to catalyse this industry.</p> <p>Expected Outcome: To address global bottlenecks in regulatory alignment, this session will emphasize the importance of mutual recognition agreements and strategies to overcome trade barriers. Through an interactive dialogue, participants will engage in an open discussion on the regulatory challenges, market access hurdles, and trade barriers faced by the pharmaceutical industry, particularly in regulated markets. The session aims to identify actionable solutions to enhance India's global competitiveness and streamline market entry for Indian pharma companies.</p>
15:30 - 15:45	<p>Tea Break</p>
16:00 - 17:30	<p>Valedictory Session</p>

ORGANISERS



Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India

The Department of Pharmaceuticals was created on the 1st of July in the year 2008 in the Ministry of Chemicals & Fertilizers with the objective to give greater focus and thrust on the development of pharmaceutical sector in the country and to regulate various complex issues related to pricing and availability of medicines at affordable prices, research & development, protection of intellectual property rights and international commitments related to pharmaceutical sector which required integration of work with other Ministries.



Federation of Indian Chambers of Commerce & Industry

Established in 1927, FICCI is the largest and oldest apex business organisation in India. Its history is closely interwoven with India's struggle for independence, its industrialization, and its emergence as one of the most rapidly growing global economies. A non-government, not-for-profit organisation, FICCI is the voice of India's business and industry. From influencing policy to encouraging debate, engaging with policy makers and civil society, FICCI articulates the views and concerns of industry. It serves its members from the Indian private and public corporate sectors and multinational companies, drawing its strength from diverse regional chambers of commerce and industry across states, reaching out to over 2,50,000 companies. FICCI provides a platform for networking and consensus building within and across sectors and is the first port of call for Indian industry, policy makers and the international business community.

For Participation, Contact:

India Pharma

Ms. Mandvi Tiwari
mandvi.tiwari@ficci.com

Ms. Himanshi Kaushik
himanshi.kaushik@ficci.com

E: lifesciences@ficci.com

India Medical Device

Ms. Beena Mulani
beena.mulani@ficci.com

Mr. Mohammad Muntazir
mohammad.muntazir@ficci.com

E: mdf@ficci.com